Neuropeptide y and neuropeptide s in major depressive disorder and post-traumatic stress disorder: Preclinical andclinical studies
*MDD is the predominant cause of “Years of life lived with disability” and “Years of life lost because of premature death” as a consequence of the disorder per se, comorbidities (cardiovascular, diabetes) and the high suicide rate. The problem is increasing due to higher depression frequency with ag...
Main Author: | A. Mathe |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2021-04-01
|
Series: | European Psychiatry |
Subjects: | |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933821000808/type/journal_article |
Similar Items
-
Intranasal Neuropeptide Y as a Potential Therapeutic for Depressive Behavior in the Rodent Single Prolonged Stress Model in Females
by: Roxanna J. Nahvi, et al.
Published: (2021-09-01) -
Antidepressant Effect of Neuropeptide Y in Models of Acute and Chronic Stress
by: Nika Andriushchenko, et al.
Published: (2022-08-01) -
Sex Differences in the Neuropeptide Y System and Implications for Stress Related Disorders
by: Roxanna J. Nahvi, et al.
Published: (2020-08-01) -
Neuropeptide Y and Stress
by: Murat Gulsun, et al.
Published: (2012-03-01) -
Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson’s Disease with Comorbid Depression versus Patients with Major Depressive Disorder
by: Per Svenningsson, et al.
Published: (2017-06-01)